Pay in 4 interest-free payments of $6.29 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
Orthop Traumatol Surg Res
ADA: Once-Weekly Cagrilintide + Semaglutide Promising in Type 2 Diabetes FRIDAY, June 12, 2026 -- Once-weekly cagrilintide, an amylin receptor agonist, plus semaglutide is efficacious for adults with type 2 diabetes inadequately controlled with diet and exercise, receiving metformin with or without a sodium glucose cotransporter 2 inhibitor (SGLT2i), and using basal insulin, according to three studies published online June 7 in The Lancet Diabetes & Endocrinology and The Lancet to coincide with the annual meeting of the American Diabetes Association, held from June 5 to 8 in New Orleans
Compare that to something like creatine, which has decades of human safety data behind it and position statements built on trials
Researchers still need larger and longer studies to define who may benefit and what risks matter most
Photochem Photobiol 84(3):582592 Funding None
US$ 22.59
US$ 28.42
US$ 26.47
US$ 28.56
US$ 29.74
US$ 20.24
